NCT00388700 2018-02-14
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
Galectin Therapeutics Inc.
Phase 2 Withdrawn
Galectin Therapeutics Inc.
University of California, Davis
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Sirtex Medical
SWOG Cancer Research Network